The week in health tech, explained in plain English.Get the free newsletter →
October 30, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

FDA Approves Sanofi's Tzield for Children With Stage 3 Diabetes

By Healthcare Technology News ·

The FDA has approved Sanofi's teplizumab, sold as Tzield, for children with stage 3 type 1 diabetes, broadening access to a drug previously cleared for delaying disease onset in higher-risk patients, according to STAT News.

The decision is notable as much for the process as the product. STAT reports the approval came after a dispute inside the agency, pitting career staff against the political appointee who leads the Center for Drug Evaluation and Research (CDER). That tension highlights how regulatory calls that were once routine science questions are increasingly entangled with leadership and political dynamics at the FDA.

For Sanofi, the expanded label opens a larger pediatric market for a therapy aimed at modifying the course of type 1 diabetes rather than just managing blood sugar. For the broader industry, the episode is a signal that sponsors and investors should watch internal FDA governance closely, since the path from data to approval now runs through contested leadership decisions, not just clinical review.

Sources

More in Government

Government

Medicare Rule Could Cut Remote Patient Monitoring Access

A proposed CMS rule could sharply reduce Medicare reimbursement for remote patient monitoring, threatening access for rural and chronically ill patients.

Why it matters: Remote monitoring has become a fast-growing, loosely overseen Medicare service, and changing how it pays could reshape home-based care for millions.

Government

HHS Launches National Plan to Overhaul US Kidney Care

HHS launched a national kidney care plan centered on prevention, dialysis reform with more patient choice, and overhauling the transplant system.

Why it matters: Kidney disease affects 1 in 7 US adults and drives major Medicare spending, so federal direction here reshapes care models and markets.

Government

FDA Approves First Once-Weekly Insulin for Children

The FDA approved Novo Nordisk's Awiqli, the first once-weekly basal insulin for children 10 and older with Type 2 diabetes.

Why it matters: Weekly rather than daily insulin could improve adherence for a growing number of children with Type 2 diabetes.